Elan Corporation, plc today announced that it has entered into a License Agreement with Abbott Pharmaceutical PR Ltd in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilize Elan' proprietary NanoCrystal Technology to develop and commercialize a single fixed-dose combination product containing the active pharmaceutical ingredients in Abbott's TriCor145 (fenofibrate) and AstraZeneca's Crestor (rosuvastatin calcium) products. Business Wire (http://home.businesswire.com/portal/site/home/?epi_menuItemID=989a6827590d7dda9cdf6023a0908a0c&epi_menuID=c791260db682611740b28e347a808a0c&epi_baseMenuID=384979e8cc48c441ef0130f5c6908a0c&ndmViewId=news_view&newsLang=en&div=1192646576&newsId=20060705005965)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Matrix Surgical’s OmniPore Implants Cleared for Marketing
The company expects to launch additional variants in early 2019.
AbbVie, Novartis Reach Deal on Humira Biosimilar
AbbVie reported Humira sales of $18.4 billion in 2017.